netFormulary Sunderland Joint Formulary NHS
NHS Sunderland Clinical Commissioning Group
City Hospitals Sunderland NHS Foundation Trust
 
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
08.01.05  Expand sub section  Other antineoplastic drugs
Cytotoxic Drug Aflibercept (Zaltrap®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Vials: 100mg/4ml, 40mg/1ml

 
Link  NICE TA 294: Aflibercept solution for injection for treating wet age‑related macular degeneration
Link  NICE TA 305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Link  NICE TA 409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Link  NICE TA 486: Aflibercept for treating choroidal neovascularisation
Link  NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Link  NICE TA346: Aflibercept for treating diabetic macular oedema
   
Atezolizumab
View adult BNF View SPC online
Formulary
Red
Cancer Drugs Fund

Atezolizumab is recommended for use within the Cancer Drugs Fund as an option for untreated locally advanced or metastatic urothelial carcinoma in adults, for whom cisplatin-based chemotherapy is unsuitable, only if the conditions of the managed access agreement for atezolizumab are followed

 
Link  NICE TA 492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
   
Avelumab Black Triangle (Bavencio ®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

20mg/ml concentrate for infusion.

 
Link  Avelumab for treating metastatic Merkel cell carcinoma (TA517)
   
Axitinib
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Film coated tablets: 1mg, 3mg, 5mg and 7mg

 
Link  NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
   
Bosutinib
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Film coated tablets: 100mg, 500mg

 
Link  NICE TA 401: Bosutinib for previously treated chronic myeloid leukaemia
   
Carfilzomib (Kyprolis®)
View adult BNF View SPC online
Formulary
Red

Vial: 60mg

 
Link  NICE TA 457: Carfilzomib for previously treated multiple myeloma
   
Ceritinib
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Capsule: 150mg

 
Link  NICE TA 395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Link  NICE TA 500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
   
Dabrafenib (Tafinlar®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Capsules: 50mg and 75mg

 
Link  NICE TA 396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Link  NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
   
DaratumumabBlack Triangle (Darzalex ®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

20mg/ml concentrate for infusion

 
Link  Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA510)14.3.18
   
Cytotoxic Drug Eribulin (Halaven®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Vial: 0.88mg/2ml
Vial: 1.32mg/3ml

 
Link  NICE TA 423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
   
Ibrutinib (Imbruvica®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Capsules: 140mg

 
Link  NICE TA 491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Link  NICE TA 502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
   
Idelalisib
View adult BNF View SPC online
Formulary
Red
Cancer Drugs Fund

Film coated tablets: 100mg, 150mg

 
Link  NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia
   
Ixazomib (Ninlaro®)
View adult BNF View SPC online
Formulary
Red

Capsules: 4mg

 
Link  NICE TA 505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
   
Lenvatinib (Lenvima®)
View adult BNF View SPC online
Formulary
Red

Capsules: 4mg and 10mg

 
Link  NICE TA 498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
   
Olaparib
View adult BNF View SPC online
Formulary
Red

Capsules: 50mg
-approved for the maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based chemotherapy in line with NICE

 
Link  NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
   
Olaratumab
View adult BNF View SPC online
Formulary
Red

Concentrate for solution for infusion: 10 mg/mL

 
Link  NICE TA 465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
   
Panobinostat (Farydak®)
View adult BNF View SPC online
Formulary
Red

Hard capsules: 10mg, 15mg, 20mg

 
Link  NICE TA 380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
   
Pembrolizumab
View adult BNF View SPC online
Formulary
Red

Vial for preparing IV infusion: 50mg

 
Link  NICE TA 357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Link  NICE TA 366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Link  NICE TA 428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Link  Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA519) 25.4.18
   
Ponatinib (Iclusig®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Tablets: 15mg, 45mg

 
Link  NICE TA 451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
   
Radium-223 dichloride
View adult BNF View SPC online
Formulary
Red
 
Link  NICE TA 412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
   
Ruxolitinib
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Tablets: 5mg, 15mg, 20mg

 
Link  NICE TA 386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
   
Talimogene laherparepvec (Imlygic®)
View adult BNF View SPC online
Formulary
Red

Solution for injection: 106 plaque forming units/1ml & 108 plaque forming units/1ml


-approved for the treatment of unresectable metastatic melanoma in line with NICE and NHS England Commissioning Policy

 
Link  NICE TA 410: Talimogene laherparepvec for treating unresectable metastatic melanoma
   
TivozanibBlack Triangle (Fotivda® )
View adult BNF View SPC online
Formulary
Red

1340mg hard capsules

Tivozanib for treating advanced renal cell carcinoma (TA512) 21.3.18

 
   
Trametinib (Mekinist®)
View adult BNF View SPC online
Formulary
Red

Film coated tablets: 500microgram, 2mg

 
Link  NICE TA 396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
   
08.01.05  Expand sub section  Amsacrine
Cytotoxic Drug Amsacrine
View adult BNF View SPC online
Formulary
Red

Injection: 75mg in 15ml

 
   
08.01.05  Expand sub section  Arsenic trioxide
Cytotoxic Drug Arsenic Trioxide
View adult BNF View SPC online
Formulary
Red

Ampoule: 10mg in 10ml
-NECDAG approved relapsed or refractory acute promyelocytic leukaemia (APL)

 
   
08.01.05  Expand sub section  Bevacizumab
Bevacizumab (Avastin®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Vial: 100mg/4ml
Syringe: 5mg/0.2ml
Solution for infusion: 25mg/1ml


*Avastin is available as a treatment option for wet AMD in situations where ophthalmologists feel, in discussion with their patients, that the licensed options are unsuitable

 
Link  NICE TA 118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
Link  NICE TA 178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA212: Colorectal cancer (metastatic) - bevacizumab
Link  NICE TA214: Breast Cancer with taxane
Link  NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Link  NICE TA263: Breast cancer with capecitabine
Link  NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Link  NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
   
08.01.05  Expand sub section  Bexarotene to top
08.01.05  Expand sub section  Bortezomib
Cytotoxic Drug Bortezomib
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Injection: 3.5mg

 
Link  NICE TA129: Multiple myeloma - bortezomib
Link  NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Link  NICE TA311: Multiple myeloma - bortezomib (induction therapy
Link  NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
   
08.01.05  Expand sub section  Brentuximab vedotin
Brentuximab vedotin (Adcetris®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Vial: 50mg

 
Link  NICE TA 446: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
   
08.01.05  Expand sub section  Cetuximab
Cetuximab
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Vials for IV infusion: 100mg in 20ml & 500mg in 100ml

 
Link  NICE TA 439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Link  NICE TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab
Link  NICE TA145: Head and neck cancer - cetuximab
Link  NICE TA172: Head and neck cancer (squamous cell carcinoma) - cetuximab
Link  NICE TA176: Colorectal cancer (first line) - cetuximab
Link  NICE TA242: TA242 Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
   
08.01.05  Expand sub section  Crisantaspase
08.01.05  Expand sub section  Dacarbazine and Temozolomide to top
Cytotoxic Drug Dacarbazine
View adult BNF View SPC online
Formulary
Red

Injection: 500mg

 
   
Cytotoxic Drug Streptozocin
View adult BNF View SPC online
Formulary
Red

unlicensedunlicensed Injection: 1g (only available on a named patient basis)

 
   
Cytotoxic Drug Temozolomide
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Capsules: 5mg, 20mg, 100mg, 250mg

 
Link  NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Link  NICE TA23: Brain cancer - temozolomide
   
08.01.05  Expand sub section  Erlotinib
Cytotoxic Drug Erlotinib (Tarceva® )
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Tablets: 25mg, 100mg & 150mg

 
Link  NICE TA162: Lung cancer (non-small-cell) 2nd line- erlotinib
Link  NICE TA227: Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy)
Link  NICE TA258: Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line)
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
08.01.05  Expand sub section  Hydroxycarbamide
Hydroxycarbamide
View adult BNF View SPC online
Formulary
Red

Capsules: 500mg
unlicensedunlicensed Suspension: 500mg in 5ml

 
   
08.01.05  Expand sub section  Imatinab
08.01.05  Expand sub section  Ipilimumab
Ipilimumab
View adult BNF View SPC online
Formulary
Red

Vial for preparing IV infusion: 50mg

 
Link  NICE TA 357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Link  NICE TA 400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Link  NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Link  NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
   
08.01.05  Expand sub section  Mitotane to top
Mitotane
View adult BNF View SPC online
Formulary
Red

Tablets: 500mg

 
   
08.01.05  Expand sub section  Panitumumab
08.01.05  Expand sub section  Pentostatin
08.01.05  Expand sub section  Platinum compounds
Cytotoxic Drug Carboplatin
View adult BNF View SPC online
Formulary
Red

Injections: 50mg in 5ml, 450mg in 45ml

 
   
Cytotoxic Drug Cisplatin
View adult BNF View SPC online
Formulary
Red

Injection: 50mg

 
   
Cytotoxic Drug Oxaliplatin
View adult BNF View SPC online
Formulary
Red

Injections: 50mg, 100mg

 
Link  NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
   
08.01.05  Expand sub section  Porfimer sodium and temoporfin
08.01.05  Expand sub section  Procarbazine to top
Cytotoxic Drug Procarbazine
View adult BNF View SPC online
Formulary
Red

Capsules: 50mg

 
   
08.01.05  Expand sub section  Protein kinase inhibitors
Afatinib
View adult BNF View SPC online
Formulary
Red

Film coated tablets: 20mg, 30mg, 40mg, 50mg

 
Link  NICE TA310: Lung cancer (non small cell, EGFR mutation positive) - afatinib
   
Crizotinib
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Capsules: 200mg, 250mg

 
Link  NICE TA 406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA 422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
   
Cytotoxic Drug Dasatinib
View adult BNF View SPC online
Formulary
Red

Tablets: 20mg, 50mg

 
Link  NICE TA 425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA 426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Everolimus (Votubia®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Capsules: 2.5mg, 5mg, 10mg


-Approved for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in accordnace line with NHS England Commissioning Policy
-a
pproved for the treatment of angiomyolipomas associated with tuberous sclerosis in line with NHS England Commissioning Policy


Tablets: 5mg and 10mg


- Clinical Commissioning Policy: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex
- Approved, in combination with exemestane, for the treatment of advanced human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor-positive breast cancer in postmenopausal women in accordance with NICE
- Approved for the treatment of advanced breast cancer after endocrine therapy in line with NICE.
-Approved for the treatment of advanced renal cell carcinoma after previous treatment in line with NICE


 

 
Link  NICE TA 421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Link  NICE TA 432: Everolimus for advanced renal cell carcinoma after previous treatment
Link  NICE TA 449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
   
Gefitinib (Iressa®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Tablets: 250mg

 
Link  NICE TA 374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Link  NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
   
Cytotoxic Drug Imatinib
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Capsules: 100mg & 400mg

 
Link  NICE TA 425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA 426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Link  NICE TA209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib
Link  NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Link  NICE TA70: Leukaemia (chronic myeloid) - imatinib
Link  NICE TA86: Gastro-intestinal stromal tumours (GIST) - imatinib
   
Nilotinib
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Capsules: 150mg, 200mg

 
Link  NICE TA 425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA 426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Link  NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
   
Nintedanib (Vargatef®)
View adult BNF View SPC online
Formulary
Red

Soft capsules: 100mg, 150mg

 
Link  NICE TA 379: Nintedanib for treating idiopathic pulmonary fibrosis
Link  NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
   
Pazopanib
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Tablets: 200mg, 400mg

 
Link  NICE TA215: Renal cell carcinoma (first line metastatic) - pazopanib
   
Picibanil
View adult BNF View SPC online
Formulary
Red

unlicensedunlicensed Injection: 100microgram
Named patient supply only

 
   
Regorafenib (Stivarga® )
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Tablets: 40mg

 
Link  NICE TA 488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
   
Sorafenib
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Tablets: 200mg

 
Link  NICE TA 474: Sorafenib for treating advanced hepatocellular carcinoma
   
Sunitinib
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Capsules: 50mg 100mg, 400mg

 
Link  NICE TA169: Renal cell carcinoma - sunitinib
Link  NICE TA178: Renal cell carcinoma
Link  NICE TA179: Gastrointestinal stromal tumours - sunitinib
   
Trifluridine and tipiracil
View adult BNF View SPC online
Formulary
Red

Tablets: 15mg/6.14mg, 20mg/8.19mg -approved for previously treated metastatic colorectal cancer in adults in line with NICE and NHS England Commissioning Policy

 
Link  NICE TA 405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
   
Vemurafenib
View adult BNF View SPC online
Formulary
Red
High Cost Medicine

Tablets: 240mg

 
Link  NICE TA 414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Link  NICE TA269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib
   
Venetoclax
View adult BNF View SPC online
Formulary
Red

Tablets: 10mg, 50mg & 100mg
-approved for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutations, and who are unsuitable for or have failed a B-cell receptor pathway inhibitor; and for the treatment of adult patients with CLL in the absence of 17p deletion ot TP53 mutation, and who are unsuitable for or have failed both chemo-immunotherapy and a B-cell receptor pathway inhibitor in line Early Access to Medicines Scientific Opinion

 
   
08.01.05  Expand sub section  Taxanes
Cytotoxic Drug Abraxane® (Paclitaxel)
View adult BNF View SPC online
Formulary
Red

Powder for suspension for infusion: 5mg - restricted for use within its current license for metastatic breast cancer patients who cannot tolerate standard taxanes.

 
Link  NICE TA 476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
   
Cytotoxic Drug Cabazitaxel
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Concentrate for IV infusion: 40mg/1ml

 
Link  NICE TA 391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
   
Cytotoxic Drug Docetaxel
View adult BNF View SPC online
Formulary
Red

Injections: 20mg, 80mg

 
Link  NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Link  NICE TA109: Breast cancer (early) - docetaxel
   
Cytotoxic Drug Paclitaxel
View adult BNF View SPC online
Formulary
Red

Concentrate for preparing IV infusion: 30mg in 5ml, 100mg in 16.7ml and 150mg in 25ml

 
Link  NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Link  NICE TA108: Breast cancer (early) - paclitaxel
Link  NICE TA55: Ovarian cancer - paclitaxel (review)
   
08.01.05  Expand sub section  Topoisomerase I inhibitors
Cytotoxic Drug Irinotecan
View adult BNF View SPC online
Formulary
Red

Injection: 40mg in 2ml & 100mg in 5ml

 
   
Cytotoxic Drug Topotecan
View adult BNF View SPC online
Formulary
Red

Capsules: 0.25mg, 1mg capsules
Vials: 1mg, 4mg

 
Link  NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Link  NICE TA183: Cervical cancer (recurrent) - topotecan
Link  NICE TA184: Lung cancer (small-cell) - topotecan
   
08.01.05  Expand sub section  Trabectedin
Cytotoxic Drug Trabectedin (Yondelis®)
View adult BNF View SPC online
Formulary
Red

Injection: 250microgram

 
Link  NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Link  NICE TA185: Soft tissue sarcoma - trabectedin
   
08.01.05  Expand sub section  Trastuzumab to top
Cytotoxic Drug Pertuzumab (Perjeta®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Vial: 420mg

 
Link  NICE TA 509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
   
Cytotoxic Drug Trastuzumab (Herceptin®)
View adult BNF View SPC online
Formulary
Red

Vial for preparing IV infusion: 150mg
Injection: 600mg s/c injection

 
Link  NICE TA107: Breast cancer (early) - trastuzumab
Link  NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Link  NICE TA34: Breast cancer - trastuzumab
   
Cytotoxic Drug Trastuzumab emtansine (Kadcyla®)
View adult BNF View SPC online
Formulary
Red
Cancer Drugs Fund
 
Link  NICE TA235: Osteosarcoma - mifamurtide
   
08.01.05  Expand sub section  Tretinoin
Tretinoin
View adult BNF View SPC online
Formulary
Red

Capsules: 10mg

 
   
08.01.05  Expand sub section  Vismodegib
 ....
 Non Formulary Items
Bexarotene  (Targretin®)

View adult BNF View SPC online
Non Formulary
 
Cabozantinib  (Cometriq®)

View adult BNF View SPC online
Non Formulary
Cancer Drugs Fund
 
Crisantaspase  (Erwinase®)

View adult BNF View SPC online
Non Formulary
 
Ixazomib  (Ninlaro®)

View adult BNF View SPC online
Non Formulary
 
Necitumumab

View adult BNF View SPC online
Non Formulary
High Cost Medicine
 
Pablociclib  (Ibrance®)

View adult BNF View SPC online
Non Formulary
 
Cytotoxic Drug  Panitumumab  (Vectibix®)

View adult BNF View SPC online
Non Formulary
High Cost Medicine
Cancer Drugs Fund
 
Cytotoxic Drug  Pentostatin  (Nipent®)

View adult BNF View SPC online
Non Formulary
 
Porfimer Sodium  (Photofrin ®)

View adult BNF View SPC online
Non Formulary
 
Sonidegib  (Odomzo®)

View adult BNF View SPC online
Non Formulary
 
Temoporfin  (Foscan®)

View adult BNF View SPC online
Non Formulary
 
Cytotoxic Drug  Vandetanib  (Caprelsa®)

View adult BNF View SPC online
Non Formulary
High Cost Medicine
Cancer Drugs Fund
 
Cytotoxic Drug  Vismodegib  (Erivedge®)

View adult BNF View SPC online
Non Formulary
High Cost Medicine
Cancer Drugs Fund
 
Vosaroxin  (Qinprezo)

View adult BNF View SPC online
Non Formulary
High Cost Medicine
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Drugs for hospital use or use by a specialist within specialist centre only. Initiation and monitoring of treatment should remain under the total responsibility of the appropriate hospital clinician or specialist. These drugs should only be prescribed under the direct supervision of that clinician or specialist and are not suitable for shared care arrangements. The drug should be supplied via the hospital or specialist centre for the duration of treatment.   

Amber

These are specialist drugs which must be initiated by secondary care specialist prescribers, but with the potential to transfer prescribing to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care. For these drugs, in order to ensure patient safety, some aspects of care must remain with the specialist due to their complexity e.g. monitoring of disease or drug response. Other more routine aspects can be transferred to the GP e.g. monitoring of adverse effects and supply of the medicine. The specific responsibilities of the specialist and GP are defined in the shared care agreement for each drug. Shared care agreements are still under development for some amber drugs. Until these are available, it would be expected that any shared care request from secondary care to a GP would be accompanied by written information which defines prescribing and monitoring responsibilities. The hospital specialist should also provide the GP with enough information and support to allow the safe transfer and ongoing management of prescribing into primary care.   

Green +

Drugs which should usually be initiated in secondary care, or by a specialist clinician, but can be safely maintained in primary care with very little or no monitoring required. In some cases there may be a further restriction for use outlined - these will be defined in each case.  

Green

These are defined as new and established drugs, which may be prescribed, initiated, changed or maintained on FP10 by the GP and, if appropriate, discontinued without recourse to secondary care. N.B. DRUGS NOT IDENTIFIED IN THE FORMULARY BY A RED, AMBER OR GREEN+ SYMBOL ARE CLASSIFIED AS GREEN.   

netFormulary